The Abeta protein of Alzheimer's Disease is an antimicrobial peptide
阿尔茨海默病的 Abeta 蛋白是一种抗菌肽
基本信息
- 批准号:8639446
- 负责人:
- 金额:$ 43.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2015-06-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAmyloid beta-ProteinAmyloid beta-Protein PrecursorAmyloidosisAnimal ModelAnimalsAttenuatedBacteriaBacterial MeningitisBehaviorBiologicalBiologyBrainCandida albicansCellsChlamydophila pneumoniaeClinical MicrobiologyDataEmployee StrikesEnterococcus faecalisEscherichia coliFutureGenerationsGrowthHumanImmune systemIn VitroInfectionInflammatoryKineticsKnockout MiceLinkListeria monocytogenesMediatingMembraneMetalsMethodsMicrobeMolecular BiologyMolecular ConformationMusNatural Killer CellsNerve DegenerationOrganismPathologyPathway interactionsPatientsPeptidesPhasePredispositionProbabilityPropertyProtein PrecursorsProteinsProtocols documentationRattusResearch PersonnelResistanceResistance to infectionRodentRoleSamplingSpecificityStaphylococcus aureusStaphylococcus epidermidisStreptococcus Group BStreptococcus pneumoniaeTestingTg2576Transgenic MiceWild Type Mouseantimicrobialantimicrobial drugantimicrobial peptideantimicrobial peptide LL-37bacterial resistancebactericidecytotoxiccytotoxicitydimerimmunoreactivityin vivoinsightmicrobialmicroorganismmouse modelneurotoxicneurotoxicitynovelpathogenpreventpublic health relevanceresearch studytrend
项目摘要
DESCRIPTION (provided by applicant): This new investigator application details a proposal to identify the normal function of A¿, the leading pathological agent in Alzheimer's disease (AD). A¿ is most often characterized as an incidental catabolic byproduct of the amyloid precursor protein (APP) with no functional role. However, a detailed comparison of A¿ and the archetypical human antimicrobial peptide (AMP) LL-37 reveals striking similarities in physiochemical and biological activities. Properties and actions cited as abnormal pathological behavior for A¿ mediate normal functions of LL-37. We propose that the physiochemical and biological activities of A¿ are consistent with a primary function as an antimicrobial peptide of the innate immune system. Consistent with our hypothesis preliminary experiments show A¿ inhibits the growth of eight clinically important microorganisms, including Candida albicans, Escherichia coli, Staphylococcus epidermidis, Streptococcus pneumoniae, Staphylococcus aureus, Listeria monocytogenes, Enterococcus faecalis, and Streptococcus agalactiae. A¿ is a more potent antimicrobial agent than LL-37 for at least two of these microorganisms. Furthermore, experiments identified an antimicrobial activity in AD brain homogenates attenuated by anti-A¿ immunodepletion. Extrapolating from the known physiochemistry of A¿ we have also identified novel metal-mediated oligomerization activities for LL-37. Oligomerization is a key step in AMP action and preliminary experiments suggest A¿ oligomers have potentiated antimicrobial activity. Consistent with a key role for oligomers in A¿s antimicrobial action our preliminary data suggest incubation of the peptide with bacterial cells also promotes oligomerization. Different bacteria species were found to generate distinct A¿ oligomers, including highly neurotoxic SDS-stable dimers and trimers. The proposed study will use established methods from clinical microbiology and molecular biology to characterize the in vitro antimicrobial activity of A¿. In addition, experiments will investigate the role of oligomers in A¿s antimicrobial action and if interaction of the peptide with microbial cells generates species with high neurotoxicity. In the final phase of our proposed study experiments will test if APP knockout mice have reduced resistance to bacterial meningitis. Conversely, transgenic mice over-expressing A¿ in the CNS will be tested for increased resistance to bacterial meningitis. Our project is a fresh approach to a long standing and largely ignored aspect of A¿ biology. We feel this line of enquiry has a high probability of yielding real and novel insights that will facilitate better strategies for ameliorating the pathological actions of A¿.
描述(由申请人提供):这一新的研究人员申请详细说明了一项关于确定阿尔茨海默病(AD)的主要病原体A?的正常功能的建议。最常见的特征是淀粉样前体蛋白(APP)附带的分解代谢副产物,没有任何功能作用。然而,将A?与典型的人类抗菌肽(AMP)LL-37进行详细比较,发现其在物理化学和生物活性上具有惊人的相似之处。被引用为异常病理行为的性质和行为介导了LL-37的正常功能。我们认为Aβ的理化和生物活性与其作为天然免疫系统的抗菌肽的主要功能是一致的。与我们的假设一致,初步实验表明,A?抑制了八种临床重要微生物的生长,包括白色念珠菌、大肠杆菌、表皮葡萄球菌、肺炎链球菌、金黄色葡萄球菌、单核细胞增生性李斯特菌、粪肠球菌和无乳链球菌。对于这些微生物中的至少两种,A?是一种比LL-37更有效的抗菌剂。此外,实验还证实了AD脑匀浆中的一种抗微生物活性,该活性可通过抗A免疫耗竭而减弱。从已知的A的物理化学推断,我们还发现了LL-37的新的金属介导的齐聚活性。齐聚是AMP作用的关键步骤,初步实验表明,A?齐聚物具有增强抗菌活性的作用。与低聚物在S抗菌作用中的关键作用相一致,我们的初步数据表明,该肽与细菌细胞孵育也促进了寡聚化。不同的细菌种类被发现产生不同的A?寡聚体,包括高度神经毒性的十二烷基硫酸钠稳定的二聚体和三聚体。这项拟议的研究将使用临床微生物学和分子生物学的既定方法来表征A?的体外抗菌活性。此外,实验还将调查低聚物在S抗菌作用中的作用,以及该肽与微生物细胞的相互作用是否会产生具有高神经毒性的物种。在我们提议的研究的最后阶段,实验将测试APP基因敲除小鼠是否降低了对细菌性脑膜炎的抵抗力。相反,在中枢神经系统中过度表达A?的转基因小鼠将被测试增强对细菌性脑膜炎的抵抗力。我们的项目是对生物学中一个长期存在且基本上被忽视的方面的一种新的方法。我们认为,这条研究路线很有可能产生真实和新颖的见解,这将促进更好的策略来改善A?的病理行为。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.
- DOI:10.1371/journal.pone.0009505
- 发表时间:2010-03-03
- 期刊:
- 影响因子:3.7
- 作者:Soscia SJ;Kirby JE;Washicosky KJ;Tucker SM;Ingelsson M;Hyman B;Burton MA;Goldstein LE;Duong S;Tanzi RE;Moir RD
- 通讯作者:Moir RD
Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease.
β 淀粉样肽可防止阿尔茨海默病小鼠和蠕虫模型中的微生物感染。
- DOI:10.1126/scitranslmed.aaf1059
- 发表时间:2016-05-25
- 期刊:
- 影响因子:17.1
- 作者:Kumar DK;Choi SH;Washicosky KJ;Eimer WA;Tucker S;Ghofrani J;Lefkowitz A;McColl G;Goldstein LE;Tanzi RE;Moir RD
- 通讯作者:Moir RD
The Emerging Role of Innate Immunity in Alzheimer's Disease.
先天免疫在阿尔茨海默病中的新作用。
- DOI:10.1038/npp.2016.226
- 发表时间:2017
- 期刊:
- 影响因子:0
- 作者:VijayaKumar,DeepakKumar;Moir,RobertD
- 通讯作者:Moir,RobertD
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT D MOIR其他文献
ROBERT D MOIR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT D MOIR', 18)}}的其他基金
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide
阿尔茨海默病的 Abeta 蛋白是一种抗菌肽
- 批准号:
8440736 - 财政年份:2010
- 资助金额:
$ 43.81万 - 项目类别:
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide
阿尔茨海默病的 Abeta 蛋白是一种抗菌肽
- 批准号:
8241126 - 财政年份:2010
- 资助金额:
$ 43.81万 - 项目类别:
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide
阿尔茨海默病的 Abeta 蛋白是一种抗菌肽
- 批准号:
7884694 - 财政年份:2010
- 资助金额:
$ 43.81万 - 项目类别:
The Abeta protein of Alzheimer's Disease is an antimicrobial peptide
阿尔茨海默病的 Abeta 蛋白是一种抗菌肽
- 批准号:
8052738 - 财政年份:2010
- 资助金额:
$ 43.81万 - 项目类别:
Targeting cross-linked amyloid protein species as a therapy for AD.
靶向交联淀粉样蛋白作为 AD 的治疗方法。
- 批准号:
7268066 - 财政年份:2006
- 资助金额:
$ 43.81万 - 项目类别:
Targeting cross-linked amyloid protein species as a therapy for AD.
靶向交联淀粉样蛋白作为 AD 的治疗方法。
- 批准号:
7076746 - 财政年份:2006
- 资助金额:
$ 43.81万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 43.81万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 43.81万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 43.81万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 43.81万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 43.81万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 43.81万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 43.81万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 43.81万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 43.81万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 43.81万 - 项目类别: